The mission of NNECOS is to promote the highest quality care for patients with cancer and blood disorders in our region through professional networking, education, and scientific research, as well as patient advocacy and public policy.


Drug Shortages Sign On Letter

Lunchtime Best Oncology Practice Series

Upcoming Topics:

  • 5/30/24 - Social Determinants of Health - presented by Takeda 
  • 6/12/24 - Special Session - Care for Everyone: Unique Needs of LGBTQ+ People with Cancer
  • 6/27/24 - Exercise to help with Fatigue - Jenny Spencer, BSN, RN, OCN

New Job Posted - NNECOS Classifieds

  • Dartmouth Cancer Center - NP or Physician Assistant - Per Diem

  • Dartmouth Cancer Center - NP or Physician Assistant

  • Dartmouth Cancer Center - Hematology Advanced Practice Provider

  • UVM Cancer Center - Faculty Scientist

  • UVM Cancer Center - 

    Medical oncologist/hematologist faculty member on the Clinical 

    Scholar Pathway at the Assistant/Associate level
  • UVM Cancer Center - 

    Physician-scientist/academic clinician to serve as Associate Director of Clinical &

    Translational Research.

  • Beth Israel Lahey Health Exeter -

    Experienced Hematology/Oncology Physician.
  • UVM Medical Center - Clinical Program Coordinator - Hematology 


Learn more about our unique funding program

Latest FDA Approvals And Drug-Related Updates

Latest FDA Approvals

  • On May 16, 2024, the Food and Drug Administration granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc.) for extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.
  • On May 15, 2024, the Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy.
  • April 29, 2024 -FDA granted traditional approval to tisotumab vedotin-tftv (Tivdak, Seagen Inc.  [now a part of Pfizer Inc.]) for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. 
  • April 23, 2024-FDA approves lutetium Lu 177 dotatate for pediatric patients 12 years and older with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
  • April 23- FDA granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.) for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.
  • April 22- FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer
  • April 18- FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer | FDA
  • April 5 - FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors
  • March 22 - FDA approves mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
  • March 19 - FDA grants accelerated approval to ponatinib with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
  • March 7 - FDA grants accelerated approval to zanubrutinib for relapsed or refractory follicular lymphoma
  • March 6 - FDA approves nivolumab in combination with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma
  • March 6 -FDA approves inotuzumab ozogamicin for pediatric patients with acute lymphoblastic leukemia 
  • March 1 - FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications
  • February 16 - FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer | FDA
  • February 16 - FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma | FDA
  • February 15 - FDA approves tepotinib for metastatic non-small cell lung cancer
  • February 13 - FDA approves irinotecan liposome for first-line treatment of metastatic pancreatic adenocarcinoma

Package/Label Updates

  • August - FDA approves new indication for  anemia without previous erythropoiesis stimulating agent use (ESAnaïve) in adult patients with very low-to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions

Code Updates

  • Effective for dates of service on or after April 1, 2024, the Centers for Medicare and Medicaid Services (CMS) has assigned the following Healthcare Common Procedure Coding System (HCPCS)* J-Code for ELREXFIO (elranatamab-bccm) injection:
J1323- Injection, elranatamab-bcmm, 1 mg

Other Updates

Business of Oncology Practice

Missed this series? Recording available

Looking Back!

Enjoy this wonderful interview with 3 of NNECOS' founding members!

Get Involved with a NNECOS Task Force



Upcoming events

Thank You Corporate Members!

Group Practice Members

Because your entire team benefits
from being a part of NNECOS!

Regional Educational Programs

Special thanks to our 2024 Diamond & Platinum Corporate Members!





Platinum Members





View the complete list of corporate members.

Northern New England Clinical Oncology Society
P.O. Box 643
Sandown, NH 03873-0643
Telephone (603) 887-1948

This website brought to you by:

Powered by Wild Apricot Membership Software